Pyrotinib is a Small Molecule owned by Jiangsu Hengrui Medicine, and is involved in 85 clinical trials, of which 18 were completed, 50 are ongoing, and 17 are planned.

Pyrotinib maleate (SHR-1258/HTI-1001) acts as HER-1 and HER-2 receptor inhibitors. The drug candidate partially blocks HER signaling and tumor growth. It operates by promoting apoptosis, discouraging angiogenesis, the formation and growth of new blood vessels that need to connect to old blood vessels to nourish tissue. Through destroying the cancerous cells and preventing a blood supply from being formed, tumors halt their growth.

The revenue for Pyrotinib is expected to reach a total of $9.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pyrotinib NPV Report.

Pyrotinib is originated and owned by Jiangsu Hengrui Medicine.

Pyrotinib Overview

Pyrotinib maleate is an anti-neoplastic agent. It is formulated as film coated tablet for oral administration. Pyrotinib maleate is indicated in combination with capecitabine for the treatment of patients with recurrent or metastatic breast cancer, who are positive for epidermal growth factor receptor 2 (HER2) and have not previously received or received trastuzumab. Patients should have received anthracycline or taxane chemotherapy before using this product.

Pyrotinib maleate (SHR-1258/HTI-1001) is under development for the treatment of HER2-positive solid tumors like metastatic biliary tract cancer, gastroesophageal junction (GEJ) adenocarcinoma, advanced or metastatic bladder urothelial cancer, triple-negative breast cancer brain metastases, gastric cancer, esophageal adenocarcinoma, colorectal cancer, solid tumor and non-small cell lung cancer. The drug candidate is administered orally. It is a tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors with Exon-20 insertion.

Jiangsu Hengrui Medicine Overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

The company reported revenues of (Renminbi) CNY25,905.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.6% over FY2020. In FY2021, the company’s operating margin was 18%, compared to an operating margin of 25.3% in FY2020. In FY2021, the company recorded a net margin of 17.5%, compared to a net margin of 22.8% in FY2020. The company reported revenues of CNY5,717.3 million for the third quarter ended September 2022, an increase of 20.4% over the previous quarter.

Quick View – Pyrotinib

Report Segments
  • Innovator (NME)
Drug Name
  • Pyrotinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.